Daily Sepsis Research Analysis
Analyzed 13 papers and selected 3 impactful papers.
Summary
Three impactful sepsis studies span diagnostics and mechanisms: a rapid integrated host–pathogen platform (MIDAS) enabling <4 h multiplex detection, a mechanistic preclinical study showing nicotinamide riboside mitigates sepsis-induced AKI via SIRT1-mediated ferroptosis suppression, and discovery of a Mid1–HRG ubiquitination axis that dampens hepatocyte antibacterial defense with therapeutic rescue in septic mice.
Research Themes
- Integrated host–pathogen diagnostics for rapid sepsis assessment
- Ferroptosis and SIRT1 as therapeutic targets in sepsis-induced organ injury
- Ubiquitination pathways (Mid1–HRG) modulating hepatic antibacterial defense
Selected Articles
1. MIDAS: rapid, multiplexed molecular profiling for integrated host-pathogen analysis.
MIDAS integrates hydrogel particle chemistry, lens-free diffraction imaging, and deep learning to quantify bacterial RNA and inflammatory proteins within 4 hours. Validation in a porcine sepsis model showed high concordance with culture, qPCR, and ELISA, supporting potential point-of-care deployment after clinical validation.
Impact: It addresses a central diagnostic gap in sepsis by combining host and pathogen measurements in a rapid, multiplexed assay with demonstrated cross-platform concordance.
Clinical Implications: If validated in humans, MIDAS could shorten time-to-targeted therapy, enable early risk stratification based on host response, and support antimicrobial stewardship through rapid pathogen detection.
Key Findings
- A single platform simultaneously quantified bacterial RNA and inflammatory proteins in under 4 hours.
- Integration of shape-encoded hydrogel particles with lens-free diffraction imaging and deep learning enabled multiplexed detection.
- Porcine sepsis specimens showed high concordance with culture, qPCR, and ELISA readouts.
Methodological Strengths
- Cross-validation against culture, qPCR, and ELISA in a clinically relevant animal model
- Rapid multiplexing combining host and pathogen metrics in a single assay
Limitations
- Proof-of-concept with no human clinical validation yet
- Sample size and diagnostic performance metrics in diverse pathogens and matrices not fully characterized
Future Directions: Prospective human studies to establish sensitivity/specificity, head-to-head comparisons with molecular panels, and expansion to fungal/viral targets and additional host biomarkers.
Addressing the need for integrated molecular analysis in complex infectious conditions requires technologies that rapidly quantify both pathogens and host responses. This is particularly relevant in sepsis research, where existing tools typically measure either microbial or host biomarkers. Here, we present MIDAS (Multiplexed Intelligent Diffraction Analysis System), a proof-of-concept platform that integrates shape-encoded hydrogel particles with lens-free diffraction imaging and deep learning-based analysis to enable simultaneous quantification of bacterial RNA and inflammatory proteins in a single system optimized for potential point-of-care use. The assay completes multiplexed measurements in under 4 h, significantly faster than standard culture workflows ( ~ 20-40 h). Beyond spiked studies, MIDAS is evaluated using specimens from a clinically relevant porcine sepsis model, showing high concordance with culture, qPCR and ELISA. Although further clinical validation is required, this flexible platform may support the development of accessible host-pathogen profiling tools with broad applications in healthcare, agriculture, food safety, and beyond.
2. The E3 ubiquitin ligase midline 1 reduces the intrinsic antibacterial activity of hepatocytes by promoting HRG degradation during sepsis.
Mid1 is upregulated in hepatocytes during sepsis, binds HRG, and promotes its ubiquitin–proteasome degradation, diminishing hepatic antibacterial activity. Hepatocyte-specific Mid1 silencing and DPP4 inhibitors improved systemic outcomes and survival in septic mice, nominating the Mid1–HRG axis as a therapeutic target.
Impact: Reveals a previously unrecognized ubiquitination pathway controlling hepatic antibacterial defense and demonstrates therapeutic rescue in vivo, including with clinically available DPP4 inhibitors.
Clinical Implications: Targeting Mid1 or stabilizing HRG could augment hepatic antibacterial capacity in sepsis; DPP4 inhibitors warrant evaluation as adjunctive therapy, pending translational studies.
Key Findings
- Mid1 expression and global ubiquitination are upregulated in hepatocytes from CLP mice and patients with acute infection.
- Mid1 directly binds HRG and targets it for ubiquitin–proteasome degradation, reducing hepatocyte antibacterial activity.
- Hepatocyte-specific Mid1 siRNA and DPP4 inhibitors improved systemic outcomes and survival in septic mice; blocking HRG abrogated protection from Mid1 knockdown.
Methodological Strengths
- Multi-modal approach integrating transcriptomics, IP–MS, and functional in vivo gene silencing
- Evidence from both animal models and patient-derived hepatocyte data
Limitations
- Preclinical study; absence of human interventional data
- Mechanistic focus on hepatocytes may not capture whole-organism immune complexity
Future Directions: Validate Mid1–HRG pathway activity in diverse human sepsis cohorts; assess timing/dosing and safety of Mid1 inhibition or HRG stabilization; and test repurposed DPP4 inhibitors in sepsis models with comorbidities.
AIMS: The ubiquitination system in hepatocytes and its direct role in antibacterial defense during sepsis remain poorly understood. This study investigated the mechanism by which the E3 ubiquitin ligase Midline 1 (Mid1) regulates the degradation of histidine-rich glycoprotein (HRG) during bacterial infection, and a proof-of-concept approach was proposed to block Mid1 and relieve hepatic sepsis. MATERIAL AND METHODS: Transcriptomic analysis of livers from a mouse cecal ligation and puncture (CLP) model was used to reveal changes in the global ubiquitination and Mid1 level. Immunoprecipitation, coupled with mass spectrometry, and native PAGE, was used to assess the proteins that bind to Mid1. The therapeutic effects of Mid1 in vivo were evaluated through hepatocyte-specific siRNAs and inhibitors. KEY FINDINGS: The Mid1 was significantly upregulated in hepatocytes from both CLP mice and patients with acute infection, accompanied by increased global ubiquitination. Inhibiting Mid1 in hepatocytes enhanced their antibacterial capacity and reduced infection-induced cellular damage in cellulo and in vivo experiments. Mid1 overexpression increased bacterial survival in AML12 hepatocyte cell lines. Mechanistically, Mid1 physically directly binds the HRG and targets it for ubiquitin-proteasomal degradation. Crucially, HRG, identified as a novel Mid1 substrate, is critical for antibacterial defense-blocking HRG abolished the protective effects of Mid1 knockdown. Hepatocyte-specific Mid1 siRNA and DPP4 inhibitors improved systemic outcomes and survival in septic mice. SIGNIFICANCE: This study highlights that the Mid1-HRG ubiquitination axis is a critical regulator of sepsis progression, suggesting a novel therapeutic strategy to augment the liver's intrinsic antibacterial activity.
3. Nicotinamide riboside alleviates sepsis-induced acute kidney injury by suppressing ferroptosis.
NR mitigates sepsis-induced AKI by upregulating SIRT1 and suppressing ferroptosis, restoring GPX4 and GSH and reducing ACSL4, FTH, and 4-HNE in vivo and in vitro. Pharmacologic inhibition or genetic knockdown of SIRT1 abrogates NR’s benefits, while SIRT1 overexpression mimics its protection.
Impact: Provides a mechanistic link between SIRT1 signaling and ferroptosis in SAKI with convergent in vivo and in vitro evidence, nominating NR and SIRT1 as therapeutic targets.
Clinical Implications: NR or SIRT1-activating strategies could be tested as adjunctive therapies to prevent or attenuate SAKI; biomarkers of ferroptosis may inform patient selection.
Key Findings
- CLP-induced sepsis reduced SIRT1 and GPX4, increased ACSL4, FTH, and 4-HNE, and impaired renal function; NR pretreatment reversed these changes.
- NR increased GSH and reduced ROS in LPS-stimulated HK-2 cells, restoring GPX4 and suppressing ferroptosis.
- SIRT1 inhibition (EX527) or knockdown abolished NR’s protective effects, whereas SIRT1 overexpression mimicked NR-mediated ferroptosis suppression.
Methodological Strengths
- Concordant in vivo (CLP mouse) and in vitro (HK-2) mechanistic validation
- Pharmacologic inhibition and genetic modulation establish SIRT1 causality
Limitations
- Pre-treatment paradigm may not reflect clinical timing of therapy
- Lack of dosing/toxicity data and human translational evidence
Future Directions: Test therapeutic windows and dosing in post-insult models; evaluate NR/SIRT1 activators in large-animal sepsis; integrate ferroptosis biomarkers for stratified clinical trials.
Sepsis-induced acute kidney injury (SAKI) is the predominant type of acute kidney injury encountered in intensive care units. Nicotinamide riboside (NR) improves kidney function in acute and chronic kidney diseases; however, its role in SAKI and the underlying mechanism remain unclear. We aimed to investigate the inhibitory effects of NR on ferroptosis in SAKI and explored the potential mechanisms involved. Cecal ligation and puncture markedly reduced SIRT1 expression in vivo, impaired renal function, decreased glutathione (GSH) activity, and glutathione peroxidase 4 (GPX4) expression, and increased the expression levels of acyl-CoA synthetase long-chain family member 4 (ACSL4), ferritin heavy chain (FTH), and 4-hydroxynonenal (4-HNE). Pretreatment with NR ameliorated these changes, whereas the protective effects of NR were reversed by treatment with the selective SIRT1 inhibitor, EX527. NR promoted SIRT1 expression in vitro and restored lipopolysaccharide (LPS)-induced downregulation of GPX4 and upregulation of ACSL4, FTH, and 4-HNE in human renal tubular epithelial (HK-2) cells. Meanwhile, NR treatment increased GSH activity and reduced the production of reactive oxygen species. EX527 treatment or SIRT1 knockdown abolished the NR-mediated ferroptosis alleviation in vitro. Additionally, we discovered that SIRT1 overexpression mimicked the protective function of NR in inhibiting ferroptosis in LPS-stimulated HK-2 cells. In light of our study findings, we concluded that NR suppressed ferroptosis by upregulating SIRT1 expression, thereby mitigating AKI induced by sepsis. This study provides a foundation for further research on SAKI and identifies potential therapeutic targets. KEY MESSAGES: NR ameliorated sepsis-induced acute kidney injury by suppressing ferroptosis. NR attenuated SIRT1 expression, resulting in ferroptosis inhibition. Using EX527 or SIRT1 knockdown abolished NR-mediated ferroptosis alleviation. SIRT1 overexpression mimicked NR's protective function in inhibiting ferroptosis.